Users of aspirin had adjusted HRs for arterial thromboembolism www.selleckchem.com/products/CP-690550.html of 0.89 (95% CI 0.66 to 1.20) and 0.78 (95% CI 0.61 to 1.01), compared with non-users of aspirin. Mortality The 30-day mortality rate was 20.1% in patients with AF and 13.9% in patients without AF (table 3). The effect of AF differed little between men and women. The presence or absence of previous

myocardial infarction had limited effect on the estimates. Mortality rates were substantially higher in patients with congestive heart failure compared with patients without heart failure, but coexisting AF and heart failure in patients only resulted in a minor increase in mortality rate compared with patients with heart failure only (23.7% vs 21.2%). In patients treated with mechanical ventilation, 30-day mortality was 34.6% in patients

with AF and 27.8% in patients without AF. Table 3 Mortality rates and HRs at 30 and 365 days following admission, by atrial fibrillation status The overall HR for death at 30 days following admission was 1.49 (95% CI 1.42 to 1.57) (table 3). After controlling for the effect of age and sex, the estimate decreased to 1.08 (95% CI 1.03 to 1.14). Further adjustment for comorbid conditions and lifestyle factors resulted in an HR of 1.00 (95% CI 0.94 to 1.05). Likewise, analyses comparing patients with and without AF and stratified by sex, previous myocardial infarction, congestive heart failure, ICU admission and mechanical ventilation yielded HRs close to a value of one in the fully adjusted model. One-year mortality was 43.7% in patients with AF and 30.3% in patients without AF. The corresponding fully adjusted HR was 1.01 (95% CI 0.98 to 1.05). Similar estimates were obtained when the analyses

were stratified according to sex, previous myocardial infarction, heart failure and ICU admission (table 3). Effect of preadmission drug use on mortality At 30 days of follow-up in patients with AF, the adjusted HR for death comparing users to non-users of vitamin K antagonists was 0.70 (95% CI 0.63 to 0.77) (table 4). Similarly, reduced mortality was observed in patients with AF who used β-blockers (aHR=0.77 (95% CI 0.70 to 0.85)) and statins (aHR=0.70 (95% CI 0.61 to 0.80)). No difference in mortality was observed in users compared with non-users of aspirin (aHR=0.98 (95% CI 0.89 to 1.08)). The values for the estimates changed very little when the follow-up period was extended to 1 year (table 4). Table 4 Effects of preadmission drug use on mortality at 30 and 365 days, by AV-951 atrial fibrillation status Increased 30-day mortality was observed in patients with AF who were users of amiodarone (aHR=1.18 (95% CI 1.00 to 1.42)) and users of digoxin (aHR=1.16 (95% CI 1.06 to 1.28)) (table 4). Uses of amiodarone and digoxin were also associated with increased 1-year mortality. Also, the use of calcium-channel blockers was associated with an increased 30-day mortality (aHR=1.17 (95% CI 1.00 to 1.36)), but no difference was observed for 1-year mortality (aHR=1.03 (95% CI 0.